BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Diana Meckbach; Ulrike Keim; Sabina Richter; Ulrike Leiter; Thomas K. Eigentler; Jürgen Bauer; Annette Pflugfelder; Petra Büttner; Claus Garbe; Benjamin Weide

doi:10.1371/journal.pone.0089218

Loading metrics

Open Access

Peer-reviewed

Research Article

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Diana Meckbach,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Ulrike Keim,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Sabina Richter,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Ulrike Leiter,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Thomas K. Eigentler,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Jürgen Bauer,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Annette Pflugfelder,

Affiliation Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany
⨯
Petra Büttner,

Affiliation Skin Cancer Research Group, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia
⨯
Claus Garbe,

Affiliations Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany, Skin Cancer Research Group, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia
⨯
Benjamin Weide

* E-mail: benjamin.weide@med.uni-tuebingen.de

Affiliations Division of Dermatooncology, Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany
⨯

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Diana Meckbach,
Ulrike Keim,
Sabina Richter,
Ulrike Leiter,
Thomas K. Eigentler,
Jürgen Bauer,
Annette Pflugfelder,
Petra Büttner,
Claus Garbe,
Benjamin Weide

Published: February 20, 2014
https://doi.org/10.1371/journal.pone.0089218

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Brain metastasis
Is the Subject Area "Brain metastasis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Melanoma
Is the Subject Area "Melanoma" applicable to this article?

Thanks for your feedback.
Mutation detection
Is the Subject Area "Mutation detection" applicable to this article?

Thanks for your feedback.
Prognosis
Is the Subject Area "Prognosis" applicable to this article?

Thanks for your feedback.
Survival analysis
Is the Subject Area "Survival analysis" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.